Theravance Biopharma and Mylan report positive results from two Phase III studies of revefenacin to treat COPD

Theravance Biopharma and Mylan have reported positive results from two replicate Phase 3 efficacy studies of revefenacin (TD-4208), an investigational, long-acting muscarinic antagonist (LAMA) and the first once-daily, nebulised bronchodilator in dev …

Source: Drug Development Technology - October 23, 2016 Category: Pharmaceuticals Source Type: news